Agilent Technologies is trading lower in pre-market activity despite positive industry developments, including the company's inclusion in a report highlighting its competitive position in the $2.8 billion nucleic acid labeling market.
The stock also saw a product expansion announcement overnight on November 10 regarding its SureSelect Cancer Research Pan Heme, a new NGS solution for genomic profiling. These company-specific updates appear to be overshadowed by broader market sentiment, as the stock faces mild pressure alongside several peers in the